CLAIMS

1. (ORIGINAL) A compound represented by the formula [I]:



[I]

wherein R^1 and R^2 are each a hydrogen atom, a halogen atom, an optionally substituted linear hydrocarbon group, or a hydroxyl group which may be substituted with an optionally substituted linear hydrocarbon group, or R^1 and R^2 may be taken together with the adjacent carbon atoms to form an optionally substituted cyclic hydrocarbon, or a dihydrofuran ring which may be substituted with an oxo group; ring A is an optionally further substituted benzene ring; B is an optionally substituted aromatic ring; X is a bond or a spacer whose main chain consists of 1 to 6 atoms; Y is an optionally esterified carboxyl group, an optionally substituted carbamoyl group, a cyano group, or an optionally substituted heterocyclic group bearing a hydrogen atom capable of being deprotonated; provided that 3-[3-[7-chloro-3-(2-[[4-chloro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl)-6-methyl-2-oxo-2H-chromen-4-yl]phenyl]-2-propionic acid, ethyl 3-[3-[7-chloro-3-(2-[[4-chloro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl)-6-methyl-2-oxo-2H-chromen-4-yl]phenyl]-2-propionate, methyl (2E)-3-[3-[7-chloro-3-(2-[[4-chloro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl)-6-methyl-2-oxo-2H-chromen-4-yl]phenyl]-2-propenoate, (2E)-3-[3-[7-chloro-3-(2-[[4-chloro-2-(trifluoromethyl)phenyl]amino]-

2-oxoethyl)-6-methyl-2-oxo-2H-chromen-4-yl]phenyl]-2-propenoic acid, ethtyl (2E)-3-[3-[7-chloro-3-(2-[[4-chloro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl)-6-methyl-2-oxo-2H-chromen-4-yl]phenyl]-2-propenoate, ethyl (2E)-3-[3-[7-chloro-3-(2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl)-6-methyl-2-oxo-2H-chromen-4-yl]phenyl]-2-propenoate and (2E)-3-[3-[7-chloro-3-(2-[[4-fluoro-2-(trifluromethyl)phenyl]amino]-2-oxoethyl)-6-methyl-2-oxo-2H-chromen-4-yl]phenyl]-2-propenoic acid are excluded, or a salt thereof.

2. (ORIGINAL) The compound according to claim 1, whererin the formula [I] is the formula [I']:



[I']

wherein ring B' is an optionally substituted benzene ring or an optionally substituted pyridine ring, R is an optionally esterified carboxyl group, or a linear hydrocarbon group which is substituted with an optionally esterified carboxyl group, and other symbols are as defined in claim 1.

3. (ORIGINAL) The compound according to claim 1, wherein R^1 and R^2 are each a hydrogen atom, a halogen atom or an optionally substituted linear hydrocarbon group, or R^1 and R^2 may be taken together with the adjacent carbon atoms to form an optionally substituted cyclic hydrocarbon.

4. (ORIGINAL) The compound according to claim 1, wherein R^1 and R^2 are each a halogen atom or an optionally substituted C_{1-7} alkyl group.

5. (ORIGINAL) The compound according to claim 1, wherein R^1 is a halogen atom and R^2 is a linear hydrocarbon group which is substituted with an optionally substituted amino group.

6. (ORIGINAL) The compound according to claim 1, wherein R^1 is a halogen atom and R^2 is a linear hydrocarbon group which is substituted with an optionally substituted cyclic amino group.

7. (ORIGINAL) The compound according to claim 1, wherein the cyclic hydrocarbon is C_{5-7} cyclic hydrocarbon.

8. (ORIGINAL) The compound according to claim 1, wherein ring B is a benzene ring which is substituted with a halogenated alkyl group and/or a halogen atom.

9. (ORIGINAL) The compound according to claim 2, wherein R is a group represented by the formula $-(CH_2)_n-R'$ wherein R' is an optionally esterified carboxyl group and n is an integer of 0 to 6.

10. (ORIGINAL) The compound according to claim 2, wherein R is a group represented by the formula $-CH=CH-(CH_2)_{n'}-R'$ wherein R' is an optionally esterified carboxyl group and n' is an integer of 0 to 4.

11. (ORIGINAL) The compound according to claim 2, wherein R is a group represented by the formula $-(CH=CH)_{n''}-R'$ wherein R' is an optionally esterified carboxyl group and n" is an integer of 1 to 3.

12. (ORIGINAL) 3-[3-[7-chloro-3-(2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl)-6-methyl-2-oxo-2H-chromen-4-yl]phenyl]propionic acid, (2E)-3-[3-[7-chloro-6-methyl-2-oxo-3-(2-oxo-2-[[2-(trifluoromethyl)phenyl]amino]ethyl)-2H-chromen-4-yl]phenyl]-2-propenoic acid, 3-[3-[7-chloro-6-methyl-2-oxo-3-(2-oxo-2-[[2-

(trifluoromethyl)phenyl]amino]ethyl)-2H-chromen-4-yl]phenyl]propionic acid, (2E)-3-[3-[6-chloro-3-(2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl)-7-methyl-2-oxo-2H-chromen-4-yl]phenyl]-2-propenoic acid, 3-[3-[6-chloro-3-(2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl)-7-methyl-2-oxo-2H-chromen-4-yl]phenyl]propionic acid, (2E)-3-(3-{7-chloro-3-(2-{[4-fluoro-2-(trifluoromethyl)phenyl]amino}-2-oxoethyl)-2-oxo-6-[(4-phenylpiperazin-1-yl)methyl]-2H-chromen-4-yl}phenyl)acrylic acid, (2E)-3-(3-{7-chloro-3-(2-{[4-chloro-2-(trifluoromethyl)phenyl]amino}-2-oxoethyl)-2-oxo-6-[(4-phenylpiperazin-1-yl)methyl]-2H-chromen-4-yl}phenyl)acrylic acid, 3-{7-chloro-3-(2-{[4-fluoro-2-(trifluoromethyl)phenyl]amino}-2-oxoethyl)-2-oxo-6-[(4-phenylpiperazin-1-yl)methyl]-2H-chromen-4-yl}benzoic acid, 3-{7-chloro-3-(2-{[4-chloro-2-(trifluoromethyl)phenyl]amino}-2-oxoethyl)-2-oxo-6-[(4-phenylpiperazin-1-yl)methyl]-2H-chromen-4-yl}benzoic acid or a salt thereof.

13. (ORIGINAL) A prodrug of the compound according to claim 1 or a salt thereof.

14. (AMENDED) A pharmaceutical composition comprising the compound according to claim 1 ~~or 13~~ or a salt thereof and a pharmaceutically acceptable carrier, excipient or diluent.

15. (ORIGINAL) The pharmaceutical composition according to claim 14, which is a lipid-rich regressing agent or an ACAT inhibitor.

16. (ORIGINAL) The pharmaceutical composition according to claim 14, which is a prophylactic or therapeutic agent against acute coronary syndrome, acute myocardial infarction, unstable angina, coronary artery restenosis after PTCA or stent placement, peripheral artery occlusion, hyperlipemia, cerebral infarction, cerebral apoplexy, Alzheimer's disease, multiple risk syndrome or metabolic syndrome, or an agent for regressing, inhibiting progression of or stabilizing an arteriosclerotic lesion.

17. (ORIGINAL) The agent for regressing, inhibiting progression of or stabilizing an arteriosclerotic lesion according to claim 16, which is combined with a HMG-CoA reductase inhibitor.

18. (ORIGINAL) A method for regressing a lipid-rich plaque or inhibiting ACAT in a mammal, which comprises administering an effective amount of the compound according to claim 1 or a salt thereof to the mammal.

19. (ORIGINAL) A method for preventing or treating acute coronary syndrome, acute myocardial infarction, unstable angina, coronary artery restenosis after PTCA or stent placement, peripheral artery occlusion, hyperlipemia, cerebral infarction, cerebral apoplexy, Alzheimer's disease, multiple risk syndrome or metabolic syndrome, or regressing, inhibiting progression of or stabilizing an arteriosclerotic lesion in a mammal, which comprises administering an effective amount of the compound according to claim 1 or a salt thereof to the mammal.

20. (AMENDED) The method for regressing, inhibiting progression of or stabilizing an arteriosclerotic lesion according to claim 19, which comprises administering the compound ~~according to claim 1~~ or a salt thereof in combination with a HMG-CoA reductase inhibitor .

21. (AMENDED) A method of making a pharmaceutical composition ~~Use of the compound according to claim 1 or a salt thereof~~ for production of a lipid-rich plaque regressing agent or an ACAT inhibitor said method comprising combining a therapeutic amount of a compound according to claim 1, or a salt there of, with a pharmaceutically acceptable carrier, excipient or diluent..

22. (ORIGINAL) A method of making a pharmaceutical composition ~~Use of the compound according to claim 1 or a salt thereof~~ for production of a prophylactic or therapeutic agent against acute coronary syndrome, acute myocardial infarction, unstable angina, coronary artery restenosis after PTCA or stent placement, peripheral artery occlusion, hyperlipemia, cerebral infarction,

cerebral apoplexy, Alzheimer's disease, multiple risk syndrome or metabolic syndrome, or an agent for regressing, inhibiting progression of or stabilizing an arteriosclerotic lesion said method comprising combining a therapeutic amount of a compound according to claim 1, or a salt there of, with a pharmaceutically acceptable carrier, excipient or diluent.

23. (AMENDED) The ~~use~~ method ~~of the compound according to claim 1 or a salt thereof for production of an agent for regressing, inhibiting progression of or stabilizing an arteriosclerotic lesion~~ according to claim 22, ~~which~~ wherein said compound is combined with a HMG-CoA reductase inhibitor.

24. (NEW) A pharmaceutical composition comprising the compound according to claim 13 or a salt thereof and a pharmaceutically acceptable carrier, excipient or diluent.